US FDA. ZILBRYSQ (zilucoplan) injection, for subcutaneous use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf. Accessed 10 Nov 2023.

Pharmaceuticals and Medical Devices Agency. ZILBRYSQ® syringe for SC injections: Japanese prescribing information. 2023. https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0003.html. Accessed 10 Nov 2023.

Howard JF Jr, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22(5):395–406.

Article  CAS  PubMed  Google Scholar 

UCB. UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan [media release]. 2023. https://www.ucb.com/stories-media/Press-Releases/article/UCB-announces-approval-of-RYSTIGGOR-rozanolixizumab-and-ZILBRYSQR-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-Japan. Accessed 25 Sep 2023.

US FDA. Zilbrysq NDA approval. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/216834Orig1s000ltr.pdf. Accessed 10 Nov 2023.

UCB. UCB announces European Commission approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis [media release]. https://www.ucb.com/sites/default/files/press_files/ac12afd8f326ccb1.pdf. Accessed 5 Dec 2023.

Kulasekararaj AG, Lehtinen A-E, Forsyth C, et al. Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria. Haematologica. 2023.

Mammen AL, Amato AA, Dimachkie MM, et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. 2023;5(2):e67-76.

Article  CAS  PubMed  Google Scholar 

Paganoni S, Berry J, Quintana M, et al. Results from the first four regimens of the HEALEY ALS Platform Trial [abstract]. Neurology. 2023;100(17 Suppl 2):PL5.004.

Google Scholar 

De Leeuw E, Van Damme KFA, Declercq J, et al. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial. Respir Res. 2022;23(1):202.

Article  PubMed  PubMed Central  Google Scholar 

Wilkinson T, Dixon R, Page C, et al. ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):691.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ako A, Glatt S, Lalla M, et al. Efficacy and safety of zilucoplan for the treatment of COVID-19 in hospitalized patients: part of the COMMUNITY platform trial. Am J Respir Crit Care Med. 2023;207(1):A1648.

Google Scholar 

UCB. UCB completes the acquisition of Ra Pharmaceuticals - to deliver differentiated therapies to patients [media release]. https://www.ucb.com/stories-media/Press-Releases/article/UCB-completes-the-acquisition-of-Ra-Pharmaceuticals-to-deliver-differentiated-therapies-to-patients. Accessed 2 Apr 2020.

Ra Pharmaceuticals. Ra Pharmaceuticals reports third quarter 2018 financial results and provides corporate update [media release]. 2018. http://www.rapharma.com. Accessed 19 Nov 2018.

Tang GQ, Tang Y, Dhamnaskar K, et al. Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol. 2023;14:1213920.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Howard JF Jr, Nowak RJ, Wolfe GI, et al. Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial. JAMA Neurol. 2020;77(5):582–92.

Article  PubMed  Google Scholar 

Muppidi S, Wolfe GI, Conaway M, et al. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727–31.

Article  PubMed  Google Scholar 

Genge A, Hussain Y, Kaminski HJ, et al. Safety and tolerability of zilucoplan in RAISE-XT: a multicenter, open-label extension study in patients with myasthenia gravis [abstract plus poster]. Muscle Nerve. 2022;66(S1):S131.

Google Scholar 

Leite MI, Bresch S, Freimer M, et al. Long-term safety, efficacy and self-injection satisfaction with zilucoplan in myasthenia gravis: an interim analysis of RAISE-XT [abstract and poster EPO-219]. In: EAN 2023. 2023.